For important risk and disclaimer information, Click here.

Industry

Biotech

Company Type

Cancer Diagnosis and Testing

Size

$15 Million

Investment Type

Equity

For additional information, please contact:
James Miehls| Managing Director
(614) 657-8398

Overview

StromaGenesis is a pre-revenue biotechnology company seeking to raise $15 million of equity to launch novel molecular diagnostic tests to improve cancer patient outcomes

 

Leveraging assets that are the product of over 18 years of academic work to develop

 

-proprietary algorithm for a more precise prostate cancer prognosis

-tissue-based immunoassay to predict therapy response in multiple solid tumors (breast, colon, prostate, glioblastoma, etc.)

-tissue-based and blood-based immunoassay as companion diagnostic test for multiple solid tumors

Opportunity

  • Current unmet need for more cancer diagnostics to provide more precise cancer patient management and treatment

 

  • Prostate Cancer Diagnostics. Scope includes preliminary and confirmatory testing and ultra-sound based diagnostics, as well as molecular diagnostics (2022 Market Size $4.1Bn, CAGR 13%)

 

  • Oncology Companion Diagnostics. Scope includes immunohistochemistry and next-generation sequencing, multiple cancer types (Market Size $3.2Bn, CAGR 13%)

 

  • Oncology Molecular Diagnostics. Scope includesinstruments and reagents, multiple cancer and molecule types (Market Size $3.7Bn, CAGR 15%)

 

  • Molecular genetic diagnostic companies, have high TTV/Revenue (4-28x)

 

  • Low COGS, high sales prices and expected profitability

Solution/Strategy

  • Molecular diagnostic test algorithm

 

  • Superior precision compared to incumbent technology in four independent patient populations (n= 487 patients)

 

  • Analysis by key opinion leaders shows unmet need and testing opportunity

 

  • Clinical trial materials accrued

 

  • Solid “moat” of comprehensive issued patents (USA and international – UK, EU, Canada, Australia, Japan)

StromaGenesis Leadership

Richard Pestell, AO., MD., PhD, MBA, Founder & CEO

 

  • Relevant start-up experience: founded/funded ProstaGene, LightSeed, EcoGenome (and sold ProstaGene, 2018)
  • Inventor of patents
  • Director of two NCI Cancer Centers (2002-2016)
  • Director Lombardi Cancer Center, Georgetown University
  • Director Sidney Kimmel Cancer Center, Thomas Jefferson University
    • Oversaw >120 clinical trials (phase 1, 2, 3)
    • Established Phase 1 program.
    • Current examiner of NCI designated Cancer Centers
  • Chairman, Department of Oncology, Georgetown University (2002)
  • Executive Vice President Thomas Jefferson University (2014)
    • annual budget of $5.6B, eleven hospitals, 30,000 employees
  • World ranked Oncology Research
  • (Google Scholar, #1 cell cycle, #5 prostate, #13 breast cancer)
  • >600 papers, >98,000 citations, H index 158
  • Advisor/Reviewer for NCI Cancer Centers, MD Anderson Breast Cancer

Specific Risks

  • Early-stage company – limited financial history, assets and cash flows
  • Liquidity – insufficient capital to acquire patents and develop and/or market products
  • Technology – new and/or preferred technologies may enter market; infringement on patents and/or trade secrets
  • Key person – lightly-staffed and fund expertise is concentrated in a few key executives
  • Competitive – Existing and/or new entrants, some with deep pockets and global operations, could develop and/or expand to compete in StromaGenesis’ markets
  • Regulatory – new legislation and/or changes in regulation could negatively impact operations and/or costs
  • Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
Learn More About StromaGenesis

Thank you for your interest in StromaGenesis.

Please fill out your information and we will contact you shortly with more information on this opportunity.

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

CONTACT US

Hi. We're not around right now. But you can send us an email and we'll get back to you, asap.

Thanks, Ken

Ken Margolis | Managing Partner Castle Placement, LLC
1460 Broadway Street, Rte 400
New York, New York 10036
(212) 418-1188 | C: (516) 712-7784
kmargolis@castleplacement.com

Sending